Denali Therapeutics Inc. Total Contract Liability
Denali Therapeutics Inc. (DNLI) had Total Contract Liability of $59.95 million as of 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2018-05-11
- 2018-03-31: Contract with Customer, Liability $59.95M.
- 2017-12-31: Contract with Customer, Liability $0.00.
| Period end | Contract with Customer, Liability |
|---|---|
| 2018-03-31 | $59.95M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $0.00 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |